First Trust Indxx NextG ETF (NASDAQ: NXTG)

Últimas noticias sobre First Trust Indxx NextG ETF (NASDAQ:NXTG)

First Trust Indxx NextG ETF

Technology

Communication Services

Real Estate

Other

Industrials

Consumer Cyclical

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies that have devoted, or have committed to devote, material resources to the research, development and application of fifth generation (5G) and next generation digital cellular technologies as they emerge.

Arista Networks Inc.

Delta Electronics Inc.

Wipro Ltd. Adr

Avago Technologi

Lg Electronics Inc. Preference Shares

Taiwan Semiconductor Mfg Ltd Sponsored Ads

Qorvo, Inc.

BT GROUP PLC

Xiaomi Corp

Xiaomi Corporation (class B)

Renesas Electronics Corp

F5 Networks Inc.

International Business Machines Corporation

Qualcomm Incorporated

Prysmian Spa

Intel Corp.

Equities

News

IDGT

NXTG

Nokia está ayudando a Openreach a construir una red de fibra de acceso abierto en el Reino Unido con su plataforma One Network Platform.

Nokia y Openreach: Transformando la banda ancha en el Reino Unido con One Network Platform

Barclays analyst Kannan Venkateshwar maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Equal-Weight and lowers the price target from $50 to $45.

Price Target

Analyst Ratings

FOXA

Barclays Maintains Equal-Weight on Fox, Lowers Price Target to $45

Barclays analyst Jared Shaw maintains Wintrust Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) with a Overweight and lowers the price target from $155 to $138.

WTFC

Barclays Maintains Overweight on Wintrust Financial, Lowers Price Target to $138

Barclays analyst Jared Shaw maintains Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Overweight and lowers the price target from $107 to $97.

Barclays Maintains Overweight on Western Alliance, Lowers Price Target to $97

Barclays analyst Jared Shaw maintains Webster Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) with a Overweight and lowers the price target from $80 to $72.

Barclays Maintains Overweight on Webster Financial, Lowers Price Target to $72

The iShares China Large-Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NASDAQ">FXI</a>) had gained as much as 4.6% to $31.39 Tuesday morning, before reversing heavily and falling 2.4% to $29.28 Tuesday afternoon as U.S.-China trade tensions <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44698697/markets-reverse-gains-as-trumps-104-china-tariff-announcement-rattles-wall-street">reached new highs</a>. 
What To Know: Beginning Wednesday at 12:01 a.m. ET, the U.S. tariff rate on Chinese goods <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44698697/markets-reverse-gains-as-trumps-104-china-tariff-announcement-rattles-wall-street">will spike to 104%</a>, a White House official confirmed.
Trump had warned of a 50% tariff increase unless Beijing removed its retaliatory duties by Tuesday. However, China stood firm, refusing to lift its 34% counter-tariffs and responding with export controls on rare earth minerals.
FXI, which tracks 50 of China's largest Hong Kong-listed firms including Alibaba Group Holding Ltd &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), took a sharp hit as investors grew wary of weakened growth prospects and intensified trade friction. The ETF faces downside pressure from expectations of supply chain disruptions and softer global demand.
Additionally, with JPMorgan estimating a <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy">60% chance</a> of a global recession, FXI remains vulnerable amid deteriorating U.S.-China relations.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44696168/apple-is-a-buying-opportunity-again-as-key-valuation-level-flashes-green-bank-of-america-says">Apple Is A &#8216;Buying Opportunity&#8217; Again As Key Valuation Level Flashes Green, Bank Of America Says</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, FXI has a 52-week high of $38.73 and a 52-week low of $23.61.

BABA

Why iShares China Large-Cap ETF (FXI) Is Falling

Barclays analyst Jared Shaw maintains Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) with a Equal-Weight and lowers the price target from $11 to $10.

Barclays Maintains Equal-Weight on Valley Ntl, Lowers Price Target to $10

Barclays analyst Jared Shaw maintains UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Overweight and lowers the price target from $139 to $125.

UMBF

Barclays Maintains Overweight on UMB Financial, Lowers Price Target to $125

Barclays analyst Jared Shaw maintains Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Underweight and lowers the price target from $73 to $70.

TCBI

Barclays Maintains Underweight on Texas Capital Bancshares, Lowers Price Target to $70

Barclays analyst Jared Shaw maintains Synovus Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Overweight and lowers the price target from $66 to $60.

Barclays Maintains Overweight on Synovus Financial, Lowers Price Target to $60

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: S&P Falls Below 5,000 Amid US-China Trade Tensions Ahead Of China Tariff Deadline, Chip Stocks Fall, Health Insurers Spike On Increased Payment Rates To Medicare Insurers

Barclays analyst Jared Shaw maintains SouthState (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) with a Overweight and lowers the price target from $120 to $115.

Barclays Maintains Overweight on SouthState, Lowers Price Target to $115

<a href="https://www.fhfa.gov/news/news-release/fannie-mae-fires-over-100-employees-for-unethical-conduct-including-the-facilitation-of-fraud">https://www.fhfa.gov/news/news-release/fannie-mae-fires-over-100-employees-for-unethical-conduct-including-the-facilitation-of-fraud</a>
 Today, the U.S. Federal Housing Finance Agency (U.S. Federal Housing FHFA) and Fannie Mae issued the following statement:
"In President Trump's housing market, there is no room for fraud, mortgage fraud, or any other deceitful act that can jeopardize the safety and soundness of the housing industry," said William J. Pulte, Chairman of the Board of Directors of Fannie Mae. "Since my swearing-in, we fired over 100 employees from Fannie Mae who we caught engaging in unethical conduct, including facilitating fraud, against our great company. &nbsp;Anyone who commits fraud against Fannie Mae does so against the American people."
"I would like to thank Director Pulte for his empowering of Fannie Mae to root out unethical conduct, including anyone facilitating fraud. We hold our employees to the highest standards, and we will continue to do so," said Priscilla Almodovar, President and Chief Executive Officer of Fannie Mae.

Management

FNMA

Fannie Mae Fires Over 100 Employees For Unethical Conduct, Including The Facilitation Of Fraud

Barclays analyst Jared Shaw maintains Prosperity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) with a Equal-Weight and lowers the price target from $88 to $86.

Barclays Maintains Equal-Weight on Prosperity Bancshares, Lowers Price Target to $86

Cryptocurrency markets are down on Tuesday, amid the White House <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44698697/markets-reverse-gains-as-trumps-104-china-tariff-announcement-rattles-wall-street">announcing a 104% tariff on Chinese goods</a>, further intensifying fears of a global trade war. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$76,817.60</td>
<td>-2.1%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$1,465.08</td>
<td>-5.6%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$105.02&nbsp;</td>
<td>-0.9%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$1.83&nbsp;</td>
<td>-3.3%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1441</td>
<td>-2%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001073&nbsp;&nbsp;</td>
<td>-5.2%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 75.8% and daily active addresses growing by 16.2%. Transactions greater than $100,000 are up from 7,593 to 13,114 in a single day. Exchanges netflows are up by 154%.</li>
<li>Coinglass data reports 101,818 traders were liquidated in the past 24 hours for $302.01 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://in.benzinga.com/etfs/new-etfs/25/04/44698247/bitwise-turns-crypto-volatility-into-yield-with-new-etf-trio">Bitwise Turns Crypto Volatility Into Yield With New ETF Trio</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44683138/xrp-will-overtake-ethereum-by-2028-standard-chartered">XRP Will Overtake Ethereum By 2028: Standard Chartered</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44696126/trump-administration-shuts-down-the-department-of-justices-crypto-crime-unit">Trump Administration Shuts Down The Department Of Justice&#8217;s Crypto Crime Unit</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44692019/ripple-acquires-prime-broker-hidden-road-for-1-25-billion">Ripple Acquires Prime Broker Hidden Road For $1.25 Billion</a></li>
<li><a href="https://www.benzinga.com/news/global/25/04/44679330/will-trump-impose-higher-tariffs-on-china-crypto-bettors-now-see-an-80-possibility">Will Trump Impose Higher Tariffs On China? Crypto Bettors Now See An 80% Possibility</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44681738/bitcoin-is-a-more-liquid-and-higher-volatility-version-of-gold-bernstein">Bitcoin Is A &#8216;More Liquid And Higher Volatility Version Of Gold&#8217;: Bernstein</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Core (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">CORE</a>)</td>
<td>&nbsp;$0.4764</td>
<td>+14%</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td>&nbsp;$0.5629</td>
<td>+11.5%</td>
</tr>
<tr>
<td>Zcash (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/zec/usd">ZEC</a>)</td>
<td>&nbsp;$34.47&nbsp;&nbsp;</td>
<td>+6.6%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1909651902872113524">believes</a> Bitcoin needs to reclaim the $80,000 level to validate a relief rally toward $91,000. Without that, the risk of a deeper breakdown remains on the table.
Doctor Profit, on the other hand, isn't convinced. 
In his latest post on X, he warns that bearish sentiment is just getting started and expects the market to continue sliding. 
He's targeting the $58,000 to $68,000 zone as a strategic buying range, calling the current market action the beginning of the real correction.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a>: Expecting the market massacre to continue, placing first buy orders between 58-68k region, the dump is far from over, the party just started for us, congratulations for all of you <a href="https://t.co/PB997aXbus">pic.twitter.com/PB997aXbus</a>
&mdash; Doctor Profit &#x1f1e8;&#x1f1ed; (@DrProfitCrypto) <a href="https://twitter.com/DrProfitCrypto/status/1909656133540643250?ref_src=twsrc%5Etfw">April 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Despite the gloomy outlook, Javon Marks <a href="https://x.com/JavonTM1/status/1909643334877859930">leans</a> bullish. 
He highlights that Bitcoin has a historical tendency to rally from oversold trend indicator levels—and we're back in that zone. Based on previous recoveries from similar setups, Marks sets a target of $116,652, calling this a recurring trend behavior.
Meanwhile, MaxBecauseBTC delivers a blunt warning, If Bitcoin fails to hold here, the cycle could be over.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> chart &#8211; We simply must hold this level. If not, cycle is likely over (unless QE ZIRP again) <a href="https://t.co/b3Rw8o4mXa">pic.twitter.com/b3Rw8o4mXa</a>
&mdash; Max (@MaxBecauseBTC) <a href="https://twitter.com/MaxBecauseBTC/status/1909670288159088994?ref_src=twsrc%5Etfw">April 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&nbsp;Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44697841/raoul-pal-says-crypto-market-nowhere-near-covid-19-peak-fear">Raoul Pal Says Crypto Market Nowhere Near COVID-19 &#8216;Peak Fear&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$CORE

$DOGE

$ETH

$KCS

$SHIB

$SOL

$XRP

$ZEC

Bitcoin, Ethereum, XRP, Dogecoin Extend Losses As White House Hammers Chinese Goods With 104% Tariff

WIIM

ARHS

RMAX

SNBR

TMHC

UEIC

Shares of homebuilders and housing-related stocks stocks are trading lower amid an overall market reversal on US-China trade tensions. Volatility in the 30-year mortgage rate could also affect housing demand.

Barclays analyst Jared Shaw maintains Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) with a Overweight and lowers the price target from $135 to $125.

PNFP

Barclays Maintains Overweight on Pinnacle Finl Partners, Lowers Price Target to $125

ADNT

APTV

ORLY

STLA

Shares of auto and auto component stocks are trading lower on continued tariff concerns ahead of the China tariff deadline. Auto part tariffs could increase costs for producers and suppliers.

Barclays analyst Jared Shaw maintains Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) with a Overweight and lowers the price target from $27 to $25.

Barclays Maintains Overweight on Old National, Lowers Price Target to $25

Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo monotherapy across all lines of therapy 1
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com&amp;esheet=54235396&amp;newsitemid=20250408873356&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=ac3870b27fa3361755a5e7e6d212b6d7">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo&#xAE;(nivolumab) plus Yervoy&#xAE; (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).1 This approval is based on the CheckMate-8HW trial, which is the largest Phase 3 trial (n=839) of immunotherapy in patients with MSI-H/dMMR mCRC, evaluating Opdivo plus Yervoy (n=354) vs. Opdivo monotherapy (n=353) in the all-lines setting and Opdivo plus Yervoy (n=202) vs. investigator's choice chemotherapy (n=101) (mFOLFOX-6 or FOLFIRI with or without bevacizumab or cetuximab) in the first-line setting.1 Opdivo plus Yervoy met the dual primary endpoints of progression free survival (PFS) when compared to Opdivo monotherapy across all lines of therapy and when compared to chemotherapy in the first-line setting, as assessed by Blinded Independent Central Review (BICR).1 This approval, granted more than two months ahead of the June 23, 2025 Prescription Drug User Fee Act goal date, follows the FDA's prior decision to grant the application Breakthrough Therapy Designation and Priority Review status.

Biotech

Bristol Myers Squibb Announces U.S. FDA Approves Opdivo Plus Yervoy A Treatment For Patients With Previously Untreated Microsatellite Instability-High Or Mismatch Repair Deficient Unresectable Or Metastatic Colorectal Cancer; Phase 3 CheckMate-8HW Trial, Opdivo Plus Yervoy Demonstrated Reduction In The Risk Of Disease Progression Or Death By 79% Vs. Chemotherapy In The First-Line Setting And By 38% Vs. Opdivo Monotherapy Across All Lines Of Therapy

Barclays analyst Jared Shaw maintains First Interstate BancSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIBK#NASDAQ">FIBK</a>) with a Underweight and lowers the price target from $31 to $28.

FIBK

Barclays Maintains Underweight on First Interstate BancSys, Lowers Price Target to $28

Comments

First Trust Indxx NextG ETF

Noticias

Últimas noticias sobre First Trust Indxx NextG ETF (NASDAQ:NXTG)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL